Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter, Fujirebio Expand Partnership to Develop Neurodegenerative Disease Assays

NEW YORK – Danaher subsidiary Beckman Coulter Diagnostics and Fujirebio announced Tuesday that they are expanding a previously announced partnership to develop diagnostic assays for neurodegenerative diseases. 

Last year, the companies announced they would partner to develop blood-based immunoassays for Alzheimer's disease, with Fujirebio developing tests for Beckman Coulter's Access portfolio of analyzers. The expanded partnership extends the two companies' research program and further refines the target analytes, including a p-tau 217 plasma assay being developed by Beckman Coulter and a beta-amyloid 1-42 plasma assay being developed by Fujirebio, the companies said in a statement. 

The new assays are being developed for use on Beckman Coulter's DxI 9000 Immunoassay analyzer, they noted. 

"Our expanded partnership with Beckman Coulter will enable increased laboratory, clinician, and patient access to more neurodegenerative biomarkers around the world," Monte Wiltse, Fujirebio Diagnostics president and CEO, said in a statement.